BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31680850)

  • 1. CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer's Disease.
    Karami A; Eriksdotter M; Kadir A; Almkvist O; Nordberg A; Darreh-Shori T
    Front Mol Neurosci; 2019; 12():239. PubMed ID: 31680850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.
    Darreh-Shori T; Kadir A; Almkvist O; Grut M; Wall A; Blomquist G; Eriksson B; Långström B; Nordberg A
    Neurobiol Aging; 2008 Feb; 29(2):168-84. PubMed ID: 17196712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.
    Kadir A; Darreh-Shori T; Almkvist O; Wall A; Grut M; Strandberg B; Ringheim A; B Eriksson ; Blomquist G; Långström B; Nordberg A
    Neurobiol Aging; 2008 Aug; 29(8):1204-17. PubMed ID: 17379359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.
    Blesa R; Davidson M; Kurz A; Reichman W; van Baelen B; Schwalen S
    Dement Geriatr Cogn Disord; 2003; 15(2):79-87. PubMed ID: 12566596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.
    Moss DE; Perez RG
    Curr Alzheimer Res; 2021; 18(13):1010-1022. PubMed ID: 34911424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulated Extracellular Choline Acetyltransferase Activity- The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway.
    Vijayaraghavan S; Karami A; Aeinehband S; Behbahani H; Grandien A; Nilsson B; Ekdahl KN; Lindblom RP; Piehl F; Darreh-Shori T
    PLoS One; 2013; 8(6):e65936. PubMed ID: 23840379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galantamine: a review of its use in Alzheimer's disease.
    Scott LJ; Goa KL
    Drugs; 2000 Nov; 60(5):1095-122. PubMed ID: 11129124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease.
    Karami A; Eyjolfsdottir H; Vijayaraghavan S; Lind G; Almqvist P; Kadir A; Linderoth B; Andreasen N; Blennow K; Wall A; Westman E; Ferreira D; Kristoffersen Wiberg M; Wahlund LO; Seiger Å; Nordberg A; Wahlberg L; Darreh-Shori T; Eriksdotter M
    Alzheimers Dement; 2015 Nov; 11(11):1316-28. PubMed ID: 25676388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintaining cognitive function in Alzheimer disease: how effective are current treatments?
    Tariot PN
    Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S26-33. PubMed ID: 11669506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cholinergic enhancing drugs on cholinergic transporters in the brain and peripheral blood lymphocytes of spontaneously hypertensive rats.
    Tomassoni D; Catalani A; Cinque C; Di Tullio MA; Tayebati SK; Cadoni A; Nwankwo IE; Traini E; Amenta F
    Curr Alzheimer Res; 2012 Jan; 9(1):120-7. PubMed ID: 22191561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
    Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
    Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
    Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.
    Maelicke A
    Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():11-8. PubMed ID: 10971047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinesterases: new roles in brain function and in Alzheimer's disease.
    Giacobini E
    Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease.
    Albuquerque EX; Santos MD; Alkondon M; Pereira EF; Maelicke A
    Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S19-25. PubMed ID: 11669505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies.
    Darreh-Shori T; Soininen H
    Curr Alzheimer Res; 2010 Feb; 7(1):67-73. PubMed ID: 20205672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.